HR and neoplasm: In this study, although no interaction between HR status and PIK3CA mutation was identified, HR+/HER2+ tumours harbouring PIK3CA mutations numerically had the lowest pCR rate (17%, 2 of 12), which is consistent with the findings of the above studies.